Videos

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.  



Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma 

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma. 

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma 

Articles

Gilberto de Lima Lopes, MD, discusses the appropriate duration of immunotherapy in lung cancer, treatment-related adverse events, and remaining challenges faced in the space.

Lopes Describes Approach for Discontinuing Immunotherapy in Metastatic Lung Cancer

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.


Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Sylvester Comprehensive Cancer Center

Latest from Sylvester Comprehensive Cancer Center

New content coming soon, please check back later.